Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models

Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993–2013

(2017) Talia Golan et al.   Journal of the National Comprehensive Cancer Network

Pancreatic cancer ascites xenograft–an expeditious model mirroring advanced therapeutic resistant disease

(2017) Talia Golan et al.   Oncotarget

Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma

(2017) Ashton A. Connor et al.   JAMA Oncology

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer

(2015) Julia Carnevale et al.   JOURNAL OF CLINICAL ONCOLOGY

Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma

(2015) Spring Holter et al.   JOURNAL OF CLINICAL ONCOLOGY

Whole genomes redefine the mutational landscape of pancreatic cancer

(2015) Nicola Waddell et al.   NATURE

Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection

(2014) Andrew E Becker   WORLD JOURNAL OF GASTROENTEROLOGY

Mechanisms of resistance to therapies targeting BRCA-mutant cancers

(2013) Christopher J Lord et al.   NATURE MEDICINE

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

(2013) N. Johnson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel

(2012) Yael Laitman et al.   BREAST CANCER RESEARCH AND TREATMENT

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

(2011) Eric A Collisson et al.   NATURE MEDICINE

A snapshot of chemoresistance to PARP inhibitors

(2011) Alberto Chiarugi   TRENDS IN PHARMACOLOGICAL SCIENCES

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY